Douglas Johnson, M.D., assistant professor of Medicine, has been named a recipient of the National Comprehensive Cancer Network (NCCN) Foundation Young Investigator Awards. The two-year grant will provide $150,000 in funding for his research on survivorship among cancer patients who receive drugs called immune checkpoint inhibitors. The formal announcement of the grant awardees was made […]
News: MelanomaNext Page »
Country music group BlackHawk recently presented a check for $20,000 to Harold (Hal) Moses, M.D., Ingram Professor of Cancer Research and director emeritus of Vanderbilt-Ingram Cancer Center (VICC), in support of cancer research. Since 2006, the group has raised and donated $100,000 to VICC in remembrance of one of the original members of the multi-platinum […]
Two therapies already in clinical development as single agents may work in combination to treat many subtypes of melanoma, a recent study suggests.
Somatic mutations, which can occur in any cell except sperm or egg, are not inheritable. Several recent studies have demonstrated that disease-causing mutations commonly alter protein folding, protein stability and protein-protein interactions. It has been difficult, however, to determine which somatic mutations identified in tumor samples “drive” the cancer development and which are just “along […]
Vanderbilt-Ingram Cancer Center (VICC) melanoma patient Gerald (Jerry) Schreiber and wife Phyllis organized and hosted the first annual Melanoma Research Golf Classic in Evansville, Indiana. The golf scramble raised $19,000 for VICC melanoma research spearheaded by Igor Puzanov, M.D., MSCI, associate professor of Medicine and director of Melanoma Clinical Research.
When something attacks you, you want to attack it back. That’s how Lillian “Tooty” Bradford views her late husband James “Jimmy” Bradford Jr.’s decision to make an initial gift to fund melanoma research at Vanderbilt-Ingram Cancer Center (VICC). The goal: to attack cancerous melanoma with the help of some of the greatest minds and researchers […]
An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation. The new study by co-first-authors Kimberly Brown Dahlman, Ph.D., Junfeng Xia, Ph.D., and Katherine Hutchinson, B.S., Vanderbilt-Ingram Cancer Center […]
Therapies targeted to a specific mutation in the BRAF gene can significantly reduce tumor burden in metastatic melanoma. But these therapies are not suitable for melanomas lacking the mutation, and even tumors carrying the BRAF mutation eventually become resistant to those therapies. Using human melanoma tumors implanted into mice, Ann Richmond, Ph.D., and colleagues assessed […]
Vanderbilt-Ingram Cancer Center cordially invites you and your guests to join us for Going for the Gold: Living Well through Cancer! Due to an overwhelming response, we have closed registration. We are thrilled to have so many people attend! Date: Saturday, June 30, 2012 Time: 9:30 a.m.-2:30 p.m. Where: Vanderbilt University Student Life Center 310 […]
Melanoma patients who are treated with new oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. A new study co-authored by Vanderbilt-Ingram Cancer Center investigators and researchers from 12 other cancer centers discovered clues that may explain what is triggering these secondary cancers. VICC’s Igor Puzanov, M.D., assistant professor […]